This study is designed to test a new medicine called PIPE-307 for people with relapsing-remitting multiple sclerosis (RRMS), a condition where the immune system attacks the brain and spine. In this study, 168 participants will be divided into three groups to either receive two different doses of PIPE-307 or a placebo, which is a harmless pill that looks like the real medicine. The study will last about 30 weeks, including a 28-day screening period to ensure eligibility, followed by 26 weeks of treatment. Doctors will check participants' health through physical exams, heart tests (ECG), and blood tests.

**Key Points to Consider:**

• The study lasts for approximately 30 weeks, with regular health check-ups.
• Participants must be aged 18-50 and able to follow the study rules, including using effective birth control.
• People with recent optic neuritis or certain medical histories may not qualify.